French Open

Lepchenko tight-lipped on meldonium claim

2016-05-24 16:24
Varvara Lepchenko (Getty Images)

Paris - America's Varvara Lepchenko refused to comment Tuesday on claims that she served a 'silent ban' after testing positive for meldonium, the drug which has put Maria Sharapova's career on hold.

The Uzbekistan-born world number 64 didn't play on the WTA Tour from February to May.

The reason, according to allegations made by Russian physio Anatoly Glebov, was that she had tested positive for 1mg of meldonium.

However, as that is below the limit set by the World Anti-Doping Agency (WADA) she was allowed to return to competition in Rome earlier this month.

Eight times Lepchenko was asked to address the allegations, but eight times she refused after losing to Russia's Ekaterina Makarova at the French Open on Tuesday.

"At the moment I have no comment on any of this. I'm here just to answer tennis questions. If you have any questions about my match, I would gladly answer them," she said.

"But otherwise, I just have no comments."

Sharapova was suspended in March after she revealed she had tested positive for meldonium at the Australian Open in January.

Read more on:    french open  |  tennis
NEXT ON SPORT24X

What To Read Next

 

Read News24’s Comments Policy

Live Video Streaming
Sport Talk

Vote

Which is your favourite Grand Slam of the year?

 
 
Men
Women
Love 2 Meet
Sport24 on Twitter

Follow Sport24 news on Twitter

English Premiership flutter

Take Sport24's "expert" tips at your peril...

Featured

The 2017/18 Absa Premiership season is under way. Can Bidvest Wits defend their title? Will Soweto giants Kaizer Chiefs or Orlando Pirates emerge victorious? Or will the bookies' favourites, Mamelodi Sundowns, taste success for a record eighth time? Stay glued to Sport24 to find out!

Latest blogs
 

Twitter Follow Sport24 on Twitter

Facebook "Like" Sport24's Facebook page

WIN Enter and win with Sport24!

BlackBerry Stay in the loop on your BlackBerry

RSS Feeds Sport news delivered really simply.

 
There are new stories on the homepage. Click here to see them.